Product Images Levetiracetam
View Photos of Packaging, Labels & Appearance
- Label Image - lbl500907368
- Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1
- Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2
- Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3
- Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4
- Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5
- Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6
- Chemical Structure - levetiracetam str
Product Label Images
The following 8 images provide visual information about the product associated with Levetiracetam NDC 50090-7368 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label Image - lbl500907368
This is a description of a product with the label "Product No. 8575-0" and a total of 120 tablets each containing 560 MG of a substance. The brand name or specific details about the product are not provided.*
Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1
This text seems to describe a figure showing the Responder Rate with a 250% Reduction from Baseline in Study 1. It includes percentages of different responses and mentions that some of the results are statistically significant versus a placebo.*
Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2
This text presents data from a study comparing the responder rate in Study 2 for a specific treatment group. The study compared the effects on patients between a placebo group and two different dosage levels of Levetiracetam (1000 mg/day and 2000 mg/day). The data shows the percentage of responders in each group, with the highest responder rate highlighted as statistically significant compared to the placebo group.*
Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3
This text describes the responder rate in Study 3, showing the percentage of participants who experienced more than a 50% reduction from baseline. The data shows that 45% of participants in the Levetiracetam 3000 mg/day group were responders compared to 14.4% in the placebo group. This difference was reported as statistically significant.*
Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4
This is a comparison of Responder Rates in Study 4 for Placebo (97 participants) and Levetiracetam (101 participants). The Responder Rate is based on a 50% reduction from baseline seizure frequency. Levetiracetam showed significant improvement compared to the placebo group based on the data presented.*
Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5
This text provides data on the Responder Rate for All Patients Ages 1 Month to < 4 Years (> 50% Reduction from Baseline) in Study 5. It shows a statistically significant result between two treatments, Placeto and Lovetracatam, with a percentage difference of 190.6%.*
Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6
This text contains data related to a study on the Responder Rate (250% Reduction from Baseline) in PGTC Seizure Frequency per Week. It compares the effectiveness of Placebo (N=84) versus Levetiracetam (N=79). The results indicate that Levetiracetam showed a statistically significant improvement compared to the placebo treatment based on the data provided.*
Chemical Structure - levetiracetam str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
